What is HC Wainwright’s Forecast for TPST FY2026 Earnings?

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Equities researchers at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Tempest Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($1.34) per share for the year, up from their previous forecast of ($2.76). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ FY2027 earnings at ($1.21) EPS and FY2028 earnings at ($0.89) EPS.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.62) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.62).

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $12.50.

Tempest Therapeutics Stock Performance

TPST opened at $1.59 on Friday. Tempest Therapeutics has a one year low of $1.50 and a one year high of $12.23. The company has a market cap of $7.84 million, a P/E ratio of -0.24 and a beta of -2.00. The business’s 50-day simple moving average is $2.28 and its 200-day simple moving average is $5.10.

Insider Activity

In other Tempest Therapeutics news, CEO Matthew Angel acquired 231,482 shares of the firm’s stock in a transaction that occurred on Tuesday, March 24th. The shares were acquired at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the transaction, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.28% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TPST. Sabby Management LLC purchased a new stake in Tempest Therapeutics in the 4th quarter valued at approximately $513,000. Vanguard Group Inc. raised its stake in Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after purchasing an additional 27,952 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Tempest Therapeutics during the 4th quarter worth about $33,000. 22.52% of the stock is owned by hedge funds and other institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune?mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator?activated receptor alpha (PPAR?) and salt?inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first?in?class PPAR? antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.